Stroke Risk Screening Scales (SRSS): Identification of Domain and Item Generation

Ruksakulpiwat, Suebsarn

doi:10.1016/j.jstrokecerebrovasdis.2021.105740

Cited by 5 publications

(6 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The WHO risk calculation tool may be utilized for individual risk assessment (ten‐year risk for a severe or lethal cardiovascular event); this is also available online or as an app 36,37 . The same applies to patients with a previous myocardial infarction, stroke, or venous thromboembolic event 38–40 . In individual, exceptional cases, concomitant medical treatment to prevent thrombosis may be tried in order to decrease the individual patient's risk 41 .…”

Section: Recommendationsmentioning

confidence: 99%

“…36,37 The same applies to patients with a previous myocardial infarction, stroke, or venous thromboembolic event. [38][39][40] In individual, exceptional cases, concomitant medical treatment to prevent thrombosis may be tried in order to decrease the individual patient's risk. 41 Established anticoagulation or pharmaceutical platelet aggregation inhibition should be taken into account.…”

Section: Recommendationsmentioning

confidence: 99%

See 1 more Smart Citation

Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases

Wohlrab

Kegel

Große

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

SummaryIn accordance with article 20 of Regulation (EC) No 726/2004, the Pharmacovigilance Risk Assessment Committee (PRAC) of the European Medicines Agency (EMA) has re‐evaluated the safety of Janus kinase inhibitors for the treatment of inflammatory diseases and formulated safety information deviating from the previous indications in the respective summary of product characteristics of the products concerned. These refer to the consideration of a possibly increased risk of venous thromboembolic or severe cardiovascular events, an increased infection rate and an increase in the prevalence of skin cancer across drugs and indications. Therefore, in patients with independent risk factors (age 65 years and older, smokers or former smokers, patients with oral contraception or hormone replacement therapy and other risk factors), it is recommended to use Janus kinase inhibitors therapeutically only if there are no suitable treatment alternatives. To facilitate a pragmatic and thorough detection of high‐risk patients in everyday clinical practice, an interdisciplinary checklist was developed that is suitable as a working tool from the perspective of the dermatologist.

show abstract

Section: Recommendationsmentioning

confidence: 99%

Section: Recommendationsmentioning

confidence: 99%

Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases

Wohlrab

Kegel

Große

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

show abstract

“…36,37 Gleiches gilt für Patienten, die in der Anamnese bereits einen Herzinfarkt, einen Schlaganfall oder ein venöses thromboembolisches Ereignis aufweisen. [38][39][40] Im Ausnahmefall kann dann eine therapiebegleitende medikamentöse Thromboseprophylaxe zur individuellen Risikominimierung im Einzelheilversuch erwogen werden. 41 Eine bereits vorbestehende Antikoagulation oder medikamentöse Thrombozytenaggregationshemmung sollten dabei berücksichtigt werden.…”

Section: Handlungsempfehlungenunclassified

Handlungsempfehlungen zur Risikominimierung beim Einsatz von Januskinase‐Inhibitoren zur Therapie chronisch‐entzündlicher Hauterkrankungen

Wohlrab

Kegel

Große

et al. 2023

J Deutsche Derma Gesell

View full text Add to dashboard Cite

ZusammenfassungDer Ausschuss für Risikobewertung (PRAC) der Europäischen Arzneimittelagentur (EMA) hat gemäß Artikel 20 der Verordnung (EG) Nr. 726/2004 die Sicherheit für Januskinase‐Inhibitoren für die Behandlung von Entzündungserkrankungen neu bewertet und von den bisherigen Hinweisen in den jeweiligen Fachinformationen der betreffenden Präparate abweichende Sicherheitsangaben formuliert. Diese beziehen sich arzneistoff‐ und indikationsübergreifend auf die Beachtung eines möglicherweise erhöhten Risikos für venöse thromboembolische oder schwere kardiovaskuläre Ereignisse, eine erhöhte Infektionsrate sowie eine Erhöhung der Prävalenz von Hautkrebs. Deshalb wird empfohlen, bei Patienten mit unabhängigen Risikofaktoren (Alter ab 65 Jahre, Raucher oder ehemalige Raucher, Patientinnen mit oraler Kontrazeption beziehungsweise Hormonersatztherapie sowie anderen Risikofaktoren) Januskinase‐Inhibitoren nur dann therapeutisch einzusetzen, wenn es keine geeigneten Behandlungsalternativen gibt. Um im klinischen Alltag eine pragmatische und sorgfältige Erfassung von Risikopatienten zu ermöglichen, wurde interdisziplinär eine Checkliste erarbeitet, die aus der Perspektive des Dermatologen als Arbeitsmittel geeignet ist.

show abstract

“…Comparison of main value categories based on value domain descriptions given by S. H. Schwartz (1992), Albrecht et al (2020), English et al (2018), Leuty & Hansen (2011), and Busque-Carrier et al ( 2022 (Sinclair et al, 2020). To transparently document and solidify our understanding of the construct and its domains, and following the examples of other authors who dedicated their papers to rigorously discuss these initial steps of measure construction (Amendola et al, 2021;Barreca et al, 2004;Ismail et al, 2021;Ruksakulpiwat, 2021;Sinclair et al, 2020), within this paper we focus exclusively on the first of the three phases: item development.…”

Section: Figurementioning

confidence: 99%

Academic Research Values: Conceptualization and Initial Steps of Measure Development

Kis¹,

Tur²,

Vaesen³

et al. 2023

Preprint

View full text Add to dashboard Cite

In this paper we draw on value theory in social psychology to conceptualize the range of motives that may influence research-related attitudes, decisions, and actions of researchers. To conceptualize academic research values, we integrate theoretical insights from the personal, work, and scientific work values literature, as well as the responses of 6 interviewees and 255 survey participants about values relevant to academic research. Finally, we propose a total of 246 academic research value items spread over 11 dimensions and 36 sub-themes. We relate our conceptualization and item proposals to existing work and provide recommendations for future measurement development. Gaining a better understanding of the different values researchers have, is useful to improve scientific careers, make science attractive to a more diverse group of individuals, and elucidate some of the mechanisms leading to exemplary and questionable science.

show abstract

Stroke Risk Screening Scales (SRSS): Identification of Domain and Item Generation

Cited by 5 publications

References 23 publications

Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases

Recommendations for risk minimization when using Janus kinase inhibitors for the treatment of chronic inflammatory skin diseases

Handlungsempfehlungen zur Risikominimierung beim Einsatz von Januskinase‐Inhibitoren zur Therapie chronisch‐entzündlicher Hauterkrankungen

Academic Research Values: Conceptualization and Initial Steps of Measure Development

Contact Info

Product

Resources

About